FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3160498512> ?p ?o ?g. }

• W3160498512 endingPage "804" @default.
• W3160498512 startingPage "790" @default.
• W3160498512 abstract "Genetic and microenvironmental factors can ‘lock’ tumor cells into a state of glutamine addiction and dependence on glutaminase (GLS). Oxidative stress and activation of the NRF2-antioxidant response pathway are conserved biomarkers for tumor sensitivity to GLS inhibitors. Glutamine antagonism reconditions the tumor microenvironment and can enhance the anticancer immune response through both direct and indirect mechanisms. Clinical trial results to date have shown tolerability of the GLS inhibitor CB-839, but mixed results with regard to efficacy, indicating the need to continue mechanistic, pharmacological, and translational research. Targeting conserved biomarkers and developing rational drug synergisms will enhance the efficacy of glutamine metabolism inhibitors in cancer therapy. Glutamine metabolism is reprogrammed during tumorigenesis and has been investigated as a promising target for cancer therapy. However, efforts to drug this process are confounded by the intrinsic metabolic heterogeneity and flexibility of tumors, as well as the risk of adverse effects on the anticancer immune response. Recent research has yielded important insights into the mechanisms that determine the tumor and the host immune responses to pharmacological perturbation of glutamine metabolism. Here, we discuss these findings and suggest that, collectively, they point toward patient stratification and drug combination strategies to maximize the efficacy of glutamine metabolism inhibitors as cancer therapeutics. Glutamine metabolism is reprogrammed during tumorigenesis and has been investigated as a promising target for cancer therapy. However, efforts to drug this process are confounded by the intrinsic metabolic heterogeneity and flexibility of tumors, as well as the risk of adverse effects on the anticancer immune response. Recent research has yielded important insights into the mechanisms that determine the tumor and the host immune responses to pharmacological perturbation of glutamine metabolism. Here, we discuss these findings and suggest that, collectively, they point toward patient stratification and drug combination strategies to maximize the efficacy of glutamine metabolism inhibitors as cancer therapeutics. the process of replenishing the intermediates of a metabolic pathway. In proliferating cells, the TCA cycle serves as a source of biosynthetic precursors and thereby loses carbon (cataplerosis). To maintain metabolic homeostasis, anaplerotic flux must match cataplerotic flux. innate and adaptive immune responses that contribute to the control of tumor growth. The immune system interacts with cancer cells in three phases – elimination, equilibrium, and escape. In the elimination phase, the immune system destroys cancer cells, and in the equilibrium phase the tumor remains stable. In the escape phase, cancer cells evade the immune system and an immunosuppressive environment is established. Cancer immunotherapy approaches aim to restore immune control of cancer. a molecule that is chemically similar to a natural metabolite, but which inhibits the normal processing of that metabolite. Antimetabolites can interfere with the functions of one or more of the enzymes that normally interact with the natural metabolite, thereby affecting the cell’s normal metabolic processes. an amidohydrolase enzyme that catalyzes the conversion of glutamine to glutamate and an ammonium ion. a cellular mechanism that coordinates the response to oxidative and electrophilic stress by upregulating the transcription factor NRF2. The transcriptional targets of NRF2 include genes encoding key mediators of the detoxification and elimination of reactive oxidants and electrophiles. NRF2 is negatively regulated by KEAP1, a tumor suppressor whose function is frequently lost in NSCLC. tumors comprise a heterogeneous population of cancer cells and also contain both resident and infiltrating host cells, such as CAFs, endothelial cells, and lymphocytes. Together with the ECM, the tumor interstitial fluid, and secreted factors, these components constitute the TME. the gene product SLC7A11 (xCT) heterodimerizes with SLC3A2 to form the plasma membrane cystine/glutamate antiporter (system xc−), which plays a role in the antioxidant response by supplying cysteine, the rate-limiting substrate for glutathione biosynthesis. The SLC7A11 gene is a transcriptional target of NRF2." @default.
• W3160498512 created "2021-05-24" @default.
• W3160498512 creator A5027191646 @default.
• W3160498512 creator A5067827137 @default.
• W3160498512 creator A5070960728 @default.
• W3160498512 creator A5078107292 @default.
• W3160498512 creator A5080667096 @default.
• W3160498512 date "2021-08-01" @default.
• W3160498512 modified "2023-10-16" @default.
• W3160498512 title "Enhancing the Efficacy of Glutamine Metabolism Inhibitors in Cancer Therapy" @default.
• W3160498512 cites W1772646934 @default.
• W3160498512 cites W1909607860 @default.
• W3160498512 cites W1969767350 @default.
• W3160498512 cites W1974684460 @default.
• W3160498512 cites W2014988241 @default.
• W3160498512 cites W2027597645 @default.
• W3160498512 cites W2033228549 @default.
• W3160498512 cites W2034530633 @default.
• W3160498512 cites W2034984029 @default.
• W3160498512 cites W2036659083 @default.
• W3160498512 cites W2037338364 @default.
• W3160498512 cites W2042680956 @default.
• W3160498512 cites W2044565982 @default.
• W3160498512 cites W2049923433 @default.
• W3160498512 cites W2050253364 @default.
• W3160498512 cites W2056174640 @default.
• W3160498512 cites W2066800748 @default.
• W3160498512 cites W2074873270 @default.
• W3160498512 cites W2079166587 @default.
• W3160498512 cites W2080880778 @default.
• W3160498512 cites W2083659501 @default.
• W3160498512 cites W2093540000 @default.
• W3160498512 cites W2099320952 @default.
• W3160498512 cites W2102501124 @default.
• W3160498512 cites W2111972302 @default.
• W3160498512 cites W2121691257 @default.
• W3160498512 cites W2126116618 @default.
• W3160498512 cites W2129917557 @default.
• W3160498512 cites W2132117833 @default.
• W3160498512 cites W2135993564 @default.
• W3160498512 cites W2166138133 @default.
• W3160498512 cites W2177855681 @default.
• W3160498512 cites W2211215064 @default.
• W3160498512 cites W2253979734 @default.
• W3160498512 cites W2264411128 @default.
• W3160498512 cites W2269870164 @default.
• W3160498512 cites W2294888209 @default.
• W3160498512 cites W2338574429 @default.
• W3160498512 cites W2502843347 @default.
• W3160498512 cites W2503851771 @default.
• W3160498512 cites W2510386957 @default.
• W3160498512 cites W2511674026 @default.
• W3160498512 cites W2516129687 @default.
• W3160498512 cites W2530547043 @default.
• W3160498512 cites W2556906723 @default.
• W3160498512 cites W2564304583 @default.
• W3160498512 cites W2582845471 @default.
• W3160498512 cites W2601158320 @default.
• W3160498512 cites W2604353006 @default.
• W3160498512 cites W2606047684 @default.
• W3160498512 cites W2606822414 @default.
• W3160498512 cites W2606901660 @default.
• W3160498512 cites W2729334679 @default.
• W3160498512 cites W2730941312 @default.
• W3160498512 cites W2758805707 @default.
• W3160498512 cites W2764232556 @default.
• W3160498512 cites W2771792762 @default.
• W3160498512 cites W2776206842 @default.
• W3160498512 cites W2783405303 @default.
• W3160498512 cites W2783764907 @default.
• W3160498512 cites W2785464562 @default.
• W3160498512 cites W2794427449 @default.
• W3160498512 cites W2799516107 @default.
• W3160498512 cites W2803962537 @default.
• W3160498512 cites W2805761162 @default.
• W3160498512 cites W2810450068 @default.
• W3160498512 cites W2884192701 @default.
• W3160498512 cites W2889574063 @default.
• W3160498512 cites W2890911268 @default.
• W3160498512 cites W2897325901 @default.
• W3160498512 cites W2899010137 @default.
• W3160498512 cites W2905294232 @default.
• W3160498512 cites W2911759816 @default.
• W3160498512 cites W2920893660 @default.
• W3160498512 cites W2922464366 @default.
• W3160498512 cites W2929070425 @default.
• W3160498512 cites W2943489129 @default.
• W3160498512 cites W2943618951 @default.
• W3160498512 cites W2947713247 @default.
• W3160498512 cites W2950853065 @default.
• W3160498512 cites W2951399368 @default.
• W3160498512 cites W2953358649 @default.
• W3160498512 cites W2973315785 @default.
• W3160498512 cites W2978044081 @default.
• W3160498512 cites W2978965391 @default.
• W3160498512 cites W2980538229 @default.
• W3160498512 cites W2985733931 @default.
• W3160498512 cites W2985764787 @default.

• next